Ischemic stroke has a high disability rate, which leads to irreversible neuronal death. The efficacy of conventional stroke treatments, including thrombolytic and neuroprotective therapies, is constrained by a number of factors, including safety concerns and inefficient drug delivery. The advent of nanomaterials has created new avenues for stroke therapy, facilitating enhanced pharmacokinetic behavior of drugs, effective drug accumulation at the target site, augmented therapeutic efficacy, and concomitant reduction in side effects. Therefore, this paper pioneers a research approach that summarized the development trend and clinical value of nanomaterials in the field of ischemic stroke through bibliometric analysis. This review provides an overview of the pathophysiological mechanisms of stroke and examines the current research trends in the use of nanomaterials in stroke management. It encompasses a multitude of domains, including targeted drug delivery systems, biosensors for the sensitive detection of biomarkers, and neuroprotective nanotechnologies capable of traversing the blood-brain barrier. Moreover, we investigate the challenges that nanomaterials encounter in the clinical translation context, including those pertaining to biocompatibility and long-term safety. These results have provided the clinical value and limitations of nanomaterials in the diagnosis and treatment of ischemic stroke from double perspectives, thereby offering new avenues for the further development of innovative nanotherapeutic tools.
Cadonilimab is the first bispecific antibody independently developed in China that simultaneously targets Programmed Cell Death Protein-1 (PD-1) and Cytotoxic T Lymphocyte-Associated Antigen-4 (CTLA-4), marking a significant milestone in both clinical applications and drug development. Through its dual mechanism of action, cadonilimab blocks PD-1 and CTLA-4 signaling pathways concurrently, thereby activating T cells and enhancing antitumor immune responses. Within the tumor microenvironment, cadonilimab promotes effector T-cell infiltration while reducing nonspecific attacks on normal tissues, thus lowering the incidence of immune-related adverse events. In comparison to conventional monospecific antibodies, cadonilimab exhibits superior selectivity and safety. Multiple studies have shown that, either as monotherapy or in combination regimens, cadonilimab exhibits promising antitumor activity and tolerability in refractory solid tumors such as advanced cervical cancer, hepatocellular carcinoma, non-small cell lung cancer, and gastric cancer, with notable efficacy even in patients with low or negative PD-L1 expression. The successful development of cadonilimab not only underscores China’s innovative capabilities in the field of cancer immunotherapy but also provides valuable insights for global drug development and clinical practice. However, most signals derive from phase I/II single-arm or small-sample studies with limited follow-up, and no randomized head-to-head trials have yet confirmed superiority over standard PD-1+CTLA-4 approaches. This review summarizes the mechanism of action, structural characteristics, clinical research progress, and future applications of cadonilimab, with the aim of offering a useful reference for research and clinical treatment while promoting its broader application in oncology.
6 September 2023 in World Journal of Clinical Cases
A carotid-cavernous fistula (CCF) is an abnormal connection between the internal carotid artery (ICA) and the cavernous sinus. Although direct CCFs typically result from trauma or as an iatrogenic complication of neuroendovascular procedures, they can occur as surgery-related complications after mechanical thrombectomy (MT). With the widespread use of MT in patients with acute ischemic stroke complicated with large vessel occlusion, it is important to document CCF following MT and how to avoid them. In this study, we present a case of a patient who developed a CCF following MT and describe in detail the characteristics of ICA tortuosity in this case. A 60-year-old woman experienced weakness in the left upper and lower limbs as well as difficulty speaking for 4 h. The neurological examination revealed left central facial paralysis and left hemiplegia, with a National Institutes of Health Stroke Scale score of 9. Head magnetic resonance imaging revealed an acute cerebral infarction in the right basal ganglia and radial crown. Magnetic resonance angiography demonstrated an occlusion of the right ICA and middle cerebral artery. Digital subtraction angiography demonstrated distal occlusion of the cervical segment of the right ICA. We performed suction combined with stent thrombectomy. Then, postoperative angiography was performed, which showed a right CCF. One month later, CCF embolization was performed, and the patient’s clinical symptoms have significantly improved 5 mo after the operation. Although a CCF is a rare complication after MT, it should be considered. Understanding the tortuosity of the internal carotid-cavernous sinus may help predict the complexity of MT and avoid this complication.
Pancreatic cancer is a highly aggressive disease that poses a significant threat to human health. Although conventional chemotherapy remains an effective t
Glioblastoma (GBM) is the most common primary malignant brain tumor of the central nervous system, marked by drug resistance, rapid progression, and extremely low survival. Immunotherapy for this disease represents a new generation of treatment following surgery, chemotherapy, and radiotherapy. The emergence of immunotherapy has significantly advanced the treatment of various solid tumors and demonstrated promising efficacy. Although PD‐1 inhibitors show potential against GBM, clinical benefit from monotherapy remains modest. A series of clinical studies have found that combining PD‐1 inhibitors with chemotherapy, radiotherapy, oncolytic viruses, vaccines, other immune checkpoint inhibitors, and CAR‐T cell therapy shows better efficacy and safety, making it an attractive therapeutic approach. In this review, we provide a summary of the approved PD‐1 inhibitors in GBM, covering their use as monotherapy and in combination therapies, along with their prospects and the latest research advances.